A detailed history of Rock Point Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Rock Point Advisors, LLC holds 380 shares of REGN stock, worth $287,587. This represents 0.11% of its overall portfolio holdings.

Number of Shares
380
Previous 380 -0.0%
Holding current value
$287,587
Previous $399,000 -0.0%
% of portfolio
0.11%
Previous 0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

SELL
$775.18 - $881.7 $15,503 - $17,634
-20 Reduced 5.0%
380 $333,000
Q3 2023

Nov 09, 2023

BUY
$692.45 - $844.37 $276,980 - $337,748
400 New
400 $329,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Rock Point Advisors, LLC Portfolio

Follow Rock Point Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Point Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rock Point Advisors, LLC with notifications on news.